Compounded weight loss drugs have been mostly off the market for about a month, but the weight loss drug industry remains as unsettled as ever.

The breakup between Novo Nordisk and Hims & Hers remains acrimonious. Recent remarks highlight the competition facing Novo ...

Synthetic food dyes are added to 1 in 5 packaged foods and drinks sold by top U.S. food manufacturers, a new study says.

Scientists at the National Institute of Environmental Health Sciences have found that dog and cat allergens are present in ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

The timing is also interesting. GLP-1s are Novo Nordisk's biggest and fastest-growing revenue stream, and competition is heating up. Eli Lilly's Zepbound is gaining traction, compounded access is ...

Despite Novo Nordisk (NVO) recently ending a partnership with Hims & Hers Health (NYSE:HIMS) to distribute its weight-loss ...

Hims & Hers Health CEO Andrew Dudum said the company will continue to sell cheap weight-loss shots despite Novo Nordisk A/S ...

Hims & Hers lost a valuable collaboration with Novo Nordisk over compounded GLP-1s. Could it hurt the company's potential to ...

Granted, defense is not a new theme. The Global X Defense Tech ETF SHLD, which has hot plays including Palantir Technologies (PLTR) and Germany's Rheinmetall (XE:RHM), has surged 54% this year. The ...